OUH agrees long COVID research collaboration with Polarean
18 May 2022
Research Translational Research
The collaboration will look at understanding the long-term effects of COVID-19 through cutting-edge MRI analysis.
Lung abnormalities found in long COVID patients with breathlessness
29 January 2022
Research Translational Research
Researchers have identified abnormalities in the lungs of long COVID patients who are experiencing breathlessness that cannot be detected with routine tests.
New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread
5 January 2022
A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.
Eileen Parkes secures Clinical Research Career Development Fellowship
16 December 2021
Eileen is awarded funding for her research into the tumour microenvironment
MP Anneliese Dodds tours Oxford cancer research
26 November 2021
Anneliese Dodds, MP for Oxford East & Chair of the Labour Party, visited the University of Oxford to learn more about the impactful work happening across departments in the field of cancer research.
World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition
24 November 2021
Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.
Advancing radiotherapy technology through clinical trials
19 November 2021
Clinical Trials Translational Research
Rob Stepney participated in a radiotherapy clinical trial in Oxford in 2021. He talks about his experience on the trial and accessing a state-of-the-art machine that uses real-time imaging to improve tumour targeting.
Oxford cancer clinical trials unit receives acclaimed nursing award
13 October 2021
Clinical Trials Translational Research
The nursing team at the Early Phase Clinical Trials Unit has been awarded the Excellence in Cancer Research Nursing Award 2021.
Anti-cancer drug derived from fungus shows promise in clinical trials
7 October 2021
A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana has found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.
Oxford to assess revolutionary multi-cancer blood test in trial, for future implementation in the NHS
15 September 2021
Clinical Trials Translational Research
A partnership between the University of Oxford and GRAIL, LLC will evaluate the use of a new, non-invasive, multi-cancer early detection test known as Galleri in suspected cancer patients.
University of Oxford Announces Opening of PanDox Phase 1 Study investigating Targeted Drug Delivery by Focused Ultrasound for Pancreatic Cancer
1 July 2021
The University of Oxford is pleased to announce commencement of enrollment for the Phase I PanDox study of thermosensitive liposomal doxorubicin triggered by focused ultrasound in patients with pancreatic cancer.
Dr Lennard Lee awarded ACP McElwain Prize for contributions to medical oncology
24 June 2021
Dr Lee (Department of Oncology) received the award to acknowledge his contributions during the COVID-19 pandemic, through the establishment of the UK Coronavirus Cancer Monitoring Project.
Further funding secured to hunt out cancer using innovative radiotherapy techniques
8 April 2021
Initial success leads to new award for Oxford researcher pushing forward new cancer-hunting radiotherapy despite lockdown.
Tripartite partnership enables access to state-of-the-art radiotherapy machine in Oxford
25 March 2021
A new ViewRay MRIdian machine is the first of its kind in the UK and will be used by the University of Oxford, OUH and GenesisCare to help improve challenging cancer treatment through faster, tailored radiotherapy.
Reprogramming tumour cells using an antimalarial drug
17 February 2021
Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.
Hidden lung damage from COVID-19 revealed in new study
2 December 2020
Research Translational Research
Early findings from a study into longer-term damage amongst patients recovering from COVID-19 suggest that the use of cutting-edge scanning techniques may detect previously unseen lung damage.